Cytomegalovirus Infections in Children with Primary and Secondary Immune Deficiencies

Overview

Journal Viruses

Publisher MDPI

Specialty Microbiology

Date 2021 Oct 26

PMID 34696432

Citations 14

Authors

Caroline M Bateman

Alison Kesson

Madeleine Powys

Melanie Wong

Emily Blyth

Affiliations

Soon will be listed here.

Abstract

Cytomegalovirus (CMV) is a human herpes virus that causes significant morbidity and mortality in immunosuppressed children. CMV primary infection causes a clinically mild disease in healthy children, usually in early childhood; the virus then utilises several mechanisms to establish host latency, which allows for periodic reactivation, particularly when the host is immunocompromised. It is this reactivation that is responsible for the significant morbidity and mortality in immunocompromised children. We review CMV infection in the primary immunodeficient host, including early identification of these infants by newborn screening to allow for CMV infection prevention strategies. Furthermore, clinical CMV is discussed in the context of children treated with secondary immunodeficiency, particularly paediatric cancer patients and children undergoing haematopoietic stem cell transplant (HSCT). Treatments for CMV are highlighted and include CMV immunotherapy.

Citing Articles

Cytomegalovirus-Reactive IgG Correlates with Increased IL-6 and IL-1β Levels, Affecting Eating Behaviours and Tactile Sensitivity in Children with Autism.

Anindya I, Sekartini R, Ariyanto I, Wiguna T, Sari N, Rahayu Y Biomedicines. 2025; 13(2).

PMID: 40002751 PMC: 11852405. DOI: 10.3390/biomedicines13020338.

Evaluation of Inborn Errors of Immunity Among Patients with Opportunistic Pulmonary Infection.

Husmann R, Lehman A, Nelson R, Pragman A Clin Chest Med. 2025; 46(1):61-75.

PMID: 39890293 PMC: 11787548. DOI: 10.1016/j.ccm.2024.10.005.

Cytomegalovirus-associated pancytopenia in a four-month-old infant: a case report.

Gyawali J, Pudasainee-Kapri S, Agrawal S, Khatri D, Adhikari S, Dhunagana P BMC Infect Dis. 2024; 24(1):1277.

PMID: 39528986 PMC: 11555845. DOI: 10.1186/s12879-024-10191-9.

Antiviral Agents for Preventing Cytomegalovirus Disease in Recipients of Hematopoietic Cell Transplantation.

Jaing T, Wang Y, Chiu C Viruses. 2024; 16(8).

PMID: 39205242 PMC: 11359103. DOI: 10.3390/v16081268.

Application of machine-learning models to predict the ganciclovir and valganciclovir exposure in children using a limited sampling strategy.

Ponthier L, Franck B, Autmizguine J, Labriffe M, Ovetchkine P, Marquet P Antimicrob Agents Chemother. 2024; 68(10):e0086024.

PMID: 39194260 PMC: 11459947. DOI: 10.1128/aac.00860-24.

References

Kirkpatrick P, Riminton S . Primary immunodeficiency diseases in Australia and New Zealand. J Clin Immunol. 2007; 27(5):517-24. DOI: 10.1007/s10875-007-9105-z. View

Peggs K, Verfuerth S, Pizzey A, Chow S, Thomson K, Mackinnon S . Cytomegalovirus-specific T cell immunotherapy promotes restoration of durable functional antiviral immunity following allogeneic stem cell transplantation. Clin Infect Dis. 2009; 49(12):1851-60. DOI: 10.1086/648422. View

Wagstaff A, Bryson H . Foscarnet. A reappraisal of its antiviral activity, pharmacokinetic properties and therapeutic use in immunocompromised patients with viral infections. Drugs. 1994; 48(2):199-226. DOI: 10.2165/00003495-199448020-00007. View

Pai S, Logan B, Griffith L, Buckley R, Parrott R, Dvorak C . Transplantation outcomes for severe combined immunodeficiency, 2000-2009. N Engl J Med. 2014; 371(5):434-46. PMC: 4183064. DOI: 10.1056/NEJMoa1401177. View

Rawlinson W . Congenital CMV international guidelines are needed to guide diagnosis, prevention and management. Acta Paediatr. 2017; 106(9):1389-1390. DOI: 10.1111/apa.13959. View

Lea A, Bryson H . Cidofovir. Drugs. 1996; 52(2):225-230; discussion 231. DOI: 10.2165/00003495-199652020-00006. View

Schleiss M . Cytomegalovirus in the neonate: immune correlates of infection and protection. Clin Dev Immunol. 2013; 2013:501801. PMC: 3760263. DOI: 10.1155/2013/501801. View

Kelesidis T, Daikos G, Boumpas D, Tsiodras S . Does rituximab increase the incidence of infectious complications? A narrative review. Int J Infect Dis. 2010; 15(1):e2-16. PMC: 8053444. DOI: 10.1016/j.ijid.2010.03.025. View

Withers B, Blyth E, Clancy L, Yong A, Fraser C, Burgess J . Long-term control of recurrent or refractory viral infections after allogeneic HSCT with third-party virus-specific T cells. Blood Adv. 2018; 1(24):2193-2205. PMC: 5737128. DOI: 10.1182/bloodadvances.2017010223. View

10.

Held G, Poschel V, Pfreundschuh M . Rituximab for the treatment of diffuse large B-cell lymphomas. Expert Rev Anticancer Ther. 2006; 6(8):1175-86. DOI: 10.1586/14737140.6.8.1175. View

11.

Teira P, Battiwalla M, Ramanathan M, Barrett A, Ahn K, Chen M . Early cytomegalovirus reactivation remains associated with increased transplant-related mortality in the current era: a CIBMTR analysis. Blood. 2016; 127(20):2427-38. PMC: 4874224. DOI: 10.1182/blood-2015-11-679639. View

12.

Strand J, Gul K, Erichsen H, Lundman E, Berge M, Tromborg A . Second-Tier Next Generation Sequencing Integrated in Nationwide Newborn Screening Provides Rapid Molecular Diagnostics of Severe Combined Immunodeficiency. Front Immunol. 2020; 11:1417. PMC: 7381310. DOI: 10.3389/fimmu.2020.01417. View

13.

Minard-Colin V, Auperin A, Pillon M, Burke G, Barkauskas D, Wheatley K . Rituximab for High-Risk, Mature B-Cell Non-Hodgkin's Lymphoma in Children. N Engl J Med. 2020; 382(23):2207-2219. PMC: 7720281. DOI: 10.1056/NEJMoa1915315. View

14.

Lucin P, Mahmutefendic H, Blagojevic Zagorac G, Tomas M . Cytomegalovirus immune evasion by perturbation of endosomal trafficking. Cell Mol Immunol. 2014; 12(2):154-69. PMC: 4654299. DOI: 10.1038/cmi.2014.85. View

15.

Weekes M, Tan S, Poole E, Talbot S, Antrobus R, Smith D . Latency-associated degradation of the MRP1 drug transporter during latent human cytomegalovirus infection. Science. 2013; 340(6129):199-202. PMC: 3683642. DOI: 10.1126/science.1235047. View

16.

Tangye S, Al-Herz W, Bousfiha A, Chatila T, Cunningham-Rundles C, Etzioni A . Human Inborn Errors of Immunity: 2019 Update on the Classification from the International Union of Immunological Societies Expert Committee. J Clin Immunol. 2020; 40(1):24-64. PMC: 7082301. DOI: 10.1007/s10875-019-00737-x. View

17.

Gugliesi F, Pasquero S, Griffante G, Scutera S, Albano C, Castillo Pacheco S . Human Cytomegalovirus and Autoimmune Diseases: Where Are We?. Viruses. 2021; 13(2). PMC: 7914970. DOI: 10.3390/v13020260. View

18.

Hughes B, Clifton R, Rouse D, Saade G, Dinsmoor M, Reddy U . A Trial of Hyperimmune Globulin to Prevent Congenital Cytomegalovirus Infection. N Engl J Med. 2021; 385(5):436-444. PMC: 8363945. DOI: 10.1056/NEJMoa1913569. View

19.

Yee A, de Ravin S, Elliott E, Ziegler J . Severe combined immunodeficiency: a national surveillance study. Pediatr Allergy Immunol. 2008; 19(4):298-302. DOI: 10.1111/j.1399-3038.2007.00646.x. View

20.

Lin A, Maloy M, Su Y, Bhatt V, DeRespiris L, Griffin M . Letermovir for primary and secondary cytomegalovirus prevention in allogeneic hematopoietic cell transplant recipients: Real-world experience. Transpl Infect Dis. 2019; 21(6):e13187. PMC: 8573720. DOI: 10.1111/tid.13187. View